This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Semaglutide treatment over 24 months reduced both BMI and muscle mass in older adults with type 2 diabetes. Grip strength initially improved then declined in men, while gait speed decreased in both sexes. Higher doses predicted greater muscle loss.
Why it matters
Older adults with diabetes are already at risk for muscle wasting. Semaglutide accelerates this loss, especially at higher doses. Doctors need to monitor muscle mass and function in elderly patients on this drug.
The numbers in context
220 semaglutide patients, 212 controls. Sarcopenia prevalence 27.7%. Significant reductions in BMI and ASMI in semaglutide group. Gait speed reduced in both sexes. Semaglutide dose, baseline ASMI, and gait speed were independent predictors of muscle loss.
How the study worked
Retrospective cohort study comparing semaglutide-treated elderly T2DM patients to matched controls. Measured ASMI, grip strength, and gait speed over 24 months. Multivariable linear regression for predictors.
Who was studied
Older adults with type 2 diabetes, with and without semaglutide treatment
What this study cannot tell us
Retrospective design. No randomization. Potential confounding by indication (sicker patients may be prescribed semaglutide). No dietary or exercise data collected. Single-center study.
Read the original research
Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.
Drug design, development and therapy, 19, 5645-5652
Citation
Ren, Qingjuan; Zhi, Lei; Liu, Hongfang. (2025). Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.. Drug design, development and therapy, 19, 5645-5652. https://doi.org/10.2147/DDDT.S531778